Fatemeh Hasani

Dr. Fatemeh Hasani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
FHFatemeh Hasani
Fatemeh Hasani
MMMahdi Masrour
Mahdi Masrour
SKSina Khamaki
Sina Khamaki
KJKimia Jazi
Kimia Jazi
SHSaba Hosseini
Saba Hosseini
MNMehrad Namazee
Mehrad Namazee
Pancreatic cancer (PC) remains a significant contributor to global cancer mortality, with limited effective diagnostic and prognostic tools. MicroRNAs (miRNAs) have emerged as promising biomarkers for PC diagnosis and prognosis. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus. Studies reporting sensitivity, specificity or area under the curve (AUC) for miRNAs in PC diagnosis, as well as hazard ratios (HRs) for survival evaluations, were included. Data extraction and quality assessment followed PRISMA guidelines. Meta‐analyses were conducted using appropriate statistical methods. The protocol is registered in PROSPERO. Diagnostic analysis included 290 evaluations, revealing an overall AUC of 0.8226 for PC diagnosis. Subgroup analyses showed varying accuracies, with blood and tissue specimens yielding higher AUC values. Promising miRNAs with AUC values above 0.8 included miR‐320, miR‐1290, miR‐93, miR‐25, miR‐451, miR‐20, miR‐21, miR‐223 and miR‐122. Prognostic analysis encompassed 46 studies, indicating significant associations between miRNA expression and overall survival (OS) and progression‐free survival (PFS). The combined HR for studies reporting OS HRs higher than one was 1.7613 (95% CI: 1.5394–2.0152, p < 0.0001; I2 = 81.7%). Notable miRNAs with prognostic significance included miR‐10, miR‐21 and miR‐221. Studies reporting OS HRs less than one had a pooled HR of 0.6805 (95% CI: 0.5862–0.7901, p < 0.0001; I2 = 65.4%). MiRNAs hold promise as diagnostic and prognostic biomarkers for PC. Blood and tissue specimens offer superior diagnostic accuracy, and several miRNAs show potential for predicting patient outcomes.

9 January 2025 in Brain and Behavior
Verified
Journal Article
Open access
FHFatemeh Hasani
Fatemeh Hasani
MMMahdi Masrour
Mahdi Masrour
SKSina Khamaki
Sina Khamaki
KJKimia Jazi
Kimia Jazi
EGErfan Ghoodjani
Erfan Ghoodjani
ATAntonio L. Teixeira
Antonio L. Teixeira
Background: This systematic review and meta‐analysis evaluates peripheral and CNS BDNF levels in glioma patients.Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta‐analysis, and meta‐regression.Results: Eight studies were included. Meta‐analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High‐grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007).Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.

8 January 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
FHFatemeh Hasani
Fatemeh Hasani
KJKimia Jazi
Kimia Jazi
KVKimia Vakili
Kimia Vakili
ATArmin Tafazolimoghadam
Armin Tafazolimoghadam
MNMehrad Namazee
Mehrad Namazee
SMSeyed Ali Mousavinejad
Seyed Ali Mousavinejad
Inflammatory biomarkers, such as leukocyte ratios, have emerged as promising tools for diagnosing and prognosticating brain gliomas. This study systematically reviewed and analysed the diagnostic and prognostic relevance of peripheral blood leukocyte ratios in glioma. Following the PRISMA guidelines, we conducted a systematic review and meta‐analysis by searching PubMed, Web of Science, and Scopus for studies published in English. Eligible studies evaluated the sensitivity, specificity, and area under the curve (AUC) of inflammatory ratios, as well as their associations with survival outcomes. Quality was assessed using the Newcastle‐Ottawa Scale. A total of 29 assessments with 13,189 observations compared the neutrophil‐to‐lymphocyte ratio (NLR) between glioma patients and non‐glioma groups, yielding a pooled standardised mean difference (SMD) of 0.445 (95% CI: 0.280–0.609, p < 0.0001; I 2 = 85.1%). When compared to healthy individuals (10 assessments, 4444 observations), glioma patients exhibited a significantly elevated NLR (SMD: 0.797, 95% CI: 0.576–1.019, p < 0.0001; I 2 = 87.5%). Compared to meningioma (5 assessments, 3227 observations), glioma patients had a significantly higher NLR (SMD: 0.352, 95% CI: 0.280–0.424, p < 0.0001; I 2 = 24.7%). In comparisons with brain metastasis (4 assessments, 428 observations), the difference was not significant (SMD: −0.112, p = 0.3315; I 2 = 44.6%). The platelet‐to‐lymphocyte ratio (PLR) (25 assessments, 12,085 observations) showed no significant difference between glioma and non‐glioma groups (SMD: 0.1291, p = 0.0836; I 2 = 81.4%). Similarly, the derived NLR (dNLR) was significantly higher in glioma patients than in non‐glioma groups (SMD: 0.2421, p < 0.0001; I 2 = 49.9%). The lymphocyte‐to‐monocyte ratio (LMR) was significantly lower in glioma compared to meningioma (SMD: −0.2989, p < 0.0001; I 2 = 0.0%). MLR analysis showed high heterogeneity ( I 2 = 99.5%) with non‐significant findings ( p = 0.4476). These findings suggest NLR and dNLR as potential biomarkers for glioma diagnosis. Peripheral blood leukocyte ratios, particularly NLR, represent valuable biomarkers for glioma diagnosis and prognosis. Further research is warranted to enhance their precision and clinical utility.

7 December 2023
Verified
Book Chapter
Open access
PDF file
FHFatemeh Hasani
Fatemeh Hasani
SHSaba Sadat Hosseini
Saba Sadat Hosseini
With the escalating economic burden of tumors, there is an urgent imperative to develop novel therapies. Activation of complement to eliminate tumors proves to be an effective approach. ABO blood group antibodies, naturally present in the body, activate the immune system by recognizing blood group antigens, resulting in the lysis and demise of red blood cells. Similarly, ABO blood group antigens can activate the human immune response and exhibit anti-tumor effects. By leveraging the immune properties of blood group antibodies in tumor treatment, a mechanism akin to the destruction of red blood cells in blood group incompatibility can be employed to eradicate tumor cells. This approach holds promise as a fresh avenue for tumor treatment and prevention of resistance.

19 October 2023
Verified
Preprint
Open access
PDF file
KJKimia Jazi
Kimia Jazi
MRMahnaz Rahimi
Mahnaz Rahimi
FHFatemeh Hasani
Fatemeh Hasani
MSMaryam Shirmohammadi
Maryam Shirmohammadi
MMMaryam Masoumi
Maryam Masoumi
Scleritis Following the booster shot of inactivated COVID-19 (Sinopharm) Vaccine in a 52-year-old WomanKimia Jazi1, Mahnaz Rahimi1, Fatemeh Hasani2, Maryam Shirmohammadi1, Maryam Masoumi3*1Student Research Committee, Faculty of Medicine, Medical University of Qom, Qom, Iran2 Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran3 Clinical Research of Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran

1 January 2024 in Case Reports in Rheumatology
Verified
Journal Article
Open access
KJKimia Jazi
Kimia Jazi
MRMahnaz Rahimi
Mahnaz Rahimi
FHFatemeh Hasani
Fatemeh Hasani
MSMaryam Shirmohammadi
Maryam Shirmohammadi
MMMaryam Masoumi
Maryam Masoumi
The only way to mitigate the spread of coronavirus disease 2019 (COVID‐19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID‐19 vaccines are no exceptions. This is a report about a 52‐year‐old female patient who presented with bilateral redness of the eyes, with normal bilateral visual acuity, postbooster dose of the Sinopharm COVID‐19 vaccine. She had no significant past history of any disease or any similar reactions after previous doses. All her physical examinations were normal. Ophthalmic examination disclosed diffuse erythema, and mild scleral edema consistent with bilateral anterior diffused scleritis with negative phenylephrine test. Thereafter, with a course of tapering doses of prednisolone (30 mg at the onset) combined with azathioprine (100 mg/day), over a 2‐week period, the condition completely resolved. Very few vaccination‐related adverse events may manifest an unrecognized underlying autoimmune vasculopathy which may also require urgent management. As in this case, ocular adverse events, as highlighted, are highly associated with undiagnosed autoimmune diseases and therefore warrant careful assessment by clinicians.